Reviewer's report

**Title:** Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer

**Version:** 2 **Date:** 17 January 2006

**Reviewer:** birgit gruenberger

**Reviewer's report:**

General
The authors describe a phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced cancer. This is a revised and improved version of a manuscript previously submitted.

-------------------------------------------------------------------------------------------------------------------

**Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)**

No major revisions

-------------------------------------------------------------------------------------------------------------------

**Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)**

Some spelling errors should be corrected:
1) page 4, 1st sentence: replace "study" with "studies"
2) page 3: what does the sentence mean: Thymidilate phosphorylase (TP) catalyses the final step of capecitabine activation form the intermediate metabolite 5-deoxyfluorouracil to fluorouracil.
3) page 3: replace .."and it is catalyzes by Dihydropyrimidine dehydrogenase" with .." ist is catalyzed by..." 

-------------------------------------------------------------------------------------------------------------------

**Discretionary Revisions (which the author can choose to ignore)**

-------------------------------------------------------------------------------------------------------------------

**What next?:** Accept after minor essential revisions

**Level of interest:** An article whose findings are important to those with closely related research interests

**Quality of written English:** Acceptable

**Statistical review:** No